News

First-Line Treatment With TKIs Associated With Improved Survival in EGFR-Positive NSCLC

05/05/2022

John Otrompke

In the 7 years following the release of treatment guidelines recommending TKIs for EGFR-positive NSCLC, OS has almost doubled among female patients younger than 50 years, according to a population-based study from the Netherlands.

In the 7 years following the...

05/05/2022

Oncology

News

What is the Preferred Treatment Option for Patients with NSCLC Harboring Uncommon EGFR Mutations?

05/05/2022

John Otrompke

Study findings suggest EGFR TKIs are the preferred treatment option for patients with NSCLC and uncommon EGFR mutations in the real-world setting.

Study findings suggest EGFR TKIs...

05/05/2022

Oncology

News

First-Line EGFR Inhibition Improves Overall Survival in EGFR–Amplified Gastroesophageal Adenocarcinoma

05/05/2022

John Otrompke

Patients with EGFR–amplified gastroesophageal adenocarcinoma derive significant benefit from EGFR inhibition in the first-line setting, according to findings from a recent analysis.

Patients with EGFR–amplified...

05/05/2022

Oncology

News

Debates and Updates of VEGF Superiority in RAS Wild-Type CRC

03/26/2022

Cathy Eng, MD, FACP, FASCO, argued for VEGF therapy versus anti-EGFR inhibition in a debate with Dr Kasi at the 2022 GDU GI conference in New York, NY.

Cathy Eng, MD, FACP, FASCO,...

03/26/2022

Oncology

News

First-Line Treatment in Left-Sided, RAS/BRAF Wild-Type Metastatic Colorectal Cancer: EGFR Inhibitors vs VEGF Inhibitors

03/26/2022

Alexa Stoia

Pashtoon M. Kasi, MD, MS, argued for EGFR inhibitors as a superior first-line treatment vs VEGF in a debate with Cathy Eng, MD, FACP, FASCO, at the 2022 Great Debates and Updates in GI Malignancies meeting.

Pashtoon M. Kasi, MD, MS, argued...

03/26/2022

Oncology

News

Very Rare EGFR Mutations Respond Heterogeneously to TKIs

03/16/2022

According to the largest real-world cohort of very rare EGFR mutations in patients with NSCLC, TKIs may cause worse outcomes during treatment.

According to the largest...

03/16/2022

Oncology

News

Highly Selective Compound Gains FDA Acceptance for Next-Gen EGFR Inhibitor in NSCLC

03/08/2022

The FDA has accepted a novel IND application for clinical trials of H002, a highly selective, fourth-generation compound to treat mutation-driven resistance for NSCLC.

The FDA has accepted a novel IND...

03/08/2022

Oncology

News

Osimertinib Overcomes Asymptomatic Brain Metastases in Lung Adenocarcinoma

03/07/2022

The first prospective study of osimertinib discovers high efficacy for patients with lung adenocarcinoma who experience asymptomatic brain metastases.

The first prospective study of...

03/07/2022

Oncology

News

Circulating Tumor DNA Predictive of Tumor Response in NSCLC

03/02/2022

A sub-analysis of the FASTACT-2 trial explores if ctDNA combined with RECIST tumor assessment results in improved responses in advanced EGFR-mutant NSCLC.

A sub-analysis of the FASTACT-2...

03/02/2022

Oncology

News

ASCO Updates Guidelines for Adjuvant Systemic, Radiation Therapy for NSCLC

02/22/2022

Two randomized trials of patients with completely resected NSCLC have prompted an amendment to ASCO Guideline Recommendations for best cancer care options of adjuvant systemic therapy and adjuvant radiation therapy.

Two randomized trials of...

02/22/2022

Oncology

Recent News

FDA Alerts

FDA Approves Zolbetuximab Plus Chemotherapy for Patients With HER2-Negative Gastric/Gastroesophageal Junction Adenocarcinoma With CLDN18.2-Positive Tumors

10/18/2024

Stephanie Holland ;

Based on results from the SPOTLIGHT and GLOW trials, the FDA has approved first-line zolbetuximab plus fluoropyrimidine and platinum-containing chemotherapy for patients with locally advanced, unresectable, or metastatic HER2-negative gastric...

Based on results from the...

10/18/2024

Oncology

Conference Coverage

First-Line Abemaciclib Plus Endocrine Therapy Improves Efficacy Among Patients With HR-Positive, HER2-Negative Advanced Breast Cancer

10/18/2024

Stephanie Holland ;

Results from the phase 2 ABIGAIL trial demonstrated that first-line abemaciclib plus endocrine therapy improves efficacy compared to standard chemotherapy among patients with HR-positive, HER2-negative advanced breast cancer.

Results from the phase 2 ABIGAIL...

10/18/2024

Oncology

FDA Approval

FDA Approves Tumor Treating Fields Wearable Device for Patients With Metastatic Non-Small Cell Lung Cancer

10/17/2024

Allison Casey ;

On October 15, 2024, the FDA granted approval to the Optune Lua, a wearable device that delivers Tumor Treating Fields, for treatment of patients with metastatic non-small cell lung cancer.

On October 15, 2024, the FDA...

10/17/2024

Oncology

News

Treatment With 131L-Apamistamab Before AlloHCT Demonstrates Efficacy, Safety Among Older Patients With R/R AML

10/15/2024

Amber Denham ;

According to phase 3 results from the SIERRA trial, anti-CD45 radioconjugate 131I-apamistamab was well-tolerated and showed a higher durable complete remission rate than standard care among older patients with relapsed/refractory acute...

According to phase 3 results...

10/15/2024

Oncology

FDA Approval

FDA Approves Inavolisib, With Palbociclib and Fulvestrant, for Endocrine-Resistant, PIK3CA-Mutated, HR-Positive, HER2-Negative Advanced Breast Cancer

10/10/2024

Allison Casey ;

The FDA has approved inavolisib, with palbociclib and fulvestrant for patients with endocrine-resistant, PIK3CA-mutated HR-positive, HER2-negative locally advanced or metastatic breast cancer.

The FDA has approved inavolisib,...

10/10/2024

Oncology

News

Momelotinib Demonstrates Improved Spleen and Symptom Requirements Among Subgroup of Patients With JAK Inhibitor-Naive Myelofibrosis

10/10/2024

Amber Denham ;

Momelotinib was well-tolerated, improved spleen and symptom responses, and reduced transfusion burden among a subgroup of patients with JAK inhibitor-naive myelofibrosis, determined an analysis of the phase 3 SIMPLIFY-1 study.

Momelotinib was well-tolerated,...

10/10/2024

Oncology

News

Nivolumab, Pomalidomide, and Elotuzumab Combination for Patients With R/R Multiple Myeloma

10/10/2024

Amber Denham ;

Nivolumab plus pomalidomide and dexamethasone plus or minus elotuzumab did not demonstrate a clinical benefit compared with pomalidomide and dexamethasone treatment for patients with relapsed/refractory multiple myeloma, according to phase 3...

Nivolumab plus pomalidomide and...

10/10/2024

Oncology

News

Evaluating Long-Term Efficacy and Safety of AlloSCT Among Patients With Peripheral T-Cell Lymphoma

10/10/2024

Amber Denham ;

While allogeneic stem cell transplantation is the preferred treatment for younger, transplant-eligible patients with relapsed/refractory peripheral T-cell lymphoma, it is currently not recommended as part of first-line consolidation,...

While allogeneic stem cell...

10/10/2024

Oncology

News

Neo/Adjuvant Pembrolizumab Significantly Improves Overall Survival for Patients With Early-Stage Triple-Negative Breast Cancer

10/09/2024

Stephanie Holland ;

According to results from the phase 3 KEYNOTE-522 trial, neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab significantly improved overall survival among patients with early-stage triple-negative breast cancer.

According to results from the...

10/09/2024

Oncology

Conference Coverage

Optimal Ifinatamab Deruxtecan Dose for Patients With Heavily Pretreated Extensive-Stage Small Cell Lung Cancer

10/09/2024

Stephanie Holland ;

According to interim analysis results from the ongoing phase 2 IDeate-Lung01 trial, 12 mg/kg of ifinatamab deruxtecan is preferable to 8 mg/kg among patients with heavily pretreated extensive-stage small cell lung cancer.

According to interim analysis...

10/09/2024

Oncology